Misako Nagasaka

7.0k total citations · 1 hit paper
205 papers, 3.2k citations indexed

About

Misako Nagasaka is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Misako Nagasaka has authored 205 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 148 papers in Oncology, 147 papers in Pulmonary and Respiratory Medicine and 51 papers in Molecular Biology. Recurrent topics in Misako Nagasaka's work include Lung Cancer Treatments and Mutations (136 papers), Lung Cancer Research Studies (52 papers) and Cancer Genomics and Diagnostics (39 papers). Misako Nagasaka is often cited by papers focused on Lung Cancer Treatments and Mutations (136 papers), Lung Cancer Research Studies (52 papers) and Cancer Genomics and Diagnostics (39 papers). Misako Nagasaka collaborates with scholars based in United States, Japan and France. Misako Nagasaka's co-authors include Sai‐Hong Ignatius Ou, Ammar Sukari, Viola W. Zhu, Shirish M. Gadgeel, Asfar S. Azmi, Shannon Zhang, Mohammed Najeeb Al Hallak, Abdurahman Alloghbi, Ziad Abuhelwa and Yiwei Li and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Misako Nagasaka

194 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

2024 76 citations Enriqueta Felip, Misako Nagasaka et al. profile →

Peers

Countries citing papers authored by Misako Nagasaka

Since Specialization

Citations

This map shows the geographic impact of Misako Nagasaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Misako Nagasaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Misako Nagasaka more than expected).

Fields of papers citing papers by Misako Nagasaka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Misako Nagasaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Misako Nagasaka. The network helps show where Misako Nagasaka may publish in the future.

Co-authorship network of co-authors of Misako Nagasaka

This figure shows the co-authorship network connecting the top 25 collaborators of Misako Nagasaka. A scholar is included among the top collaborators of Misako Nagasaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Misako Nagasaka. Misako Nagasaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Consolidative radiotherapy in oligometastatic and oligoprogressive NSCLC: A systematic review 2025 ·Critical Reviews in Oncology/Hematology ·(unknown), (unknown), Jeremy P. Harris, Misako Nagasaka	3
2	Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges 2025 ·Signal Transduction and Targeted Therapy ·Khalil Choucair, (unknown), Md. Hafiz Uddin, Misako Nagasaka, Mohammed Najeeb Al Hallak, Philip A. Philip, (unknown), Boris Pasche, Asfar S. Azmi	2
3	1289P Pooled efficacy and safety from 2 pivotal phase II trials of taletrectinib in patients (Pts) with advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC) 2024 ·Annals of Oncology ·M. Pérol, Wei Li, Nathan A. Pennell, Guimei Liu, (unknown), Filippo de Braud, Misako Nagasaka, Enriqueta Felip, (unknown), (unknown), Hongying Fan, Xu Wang, Bin Yan, (unknown), (unknown), Lyudmila Bazhenova, (unknown)	3
4	PP01.115 Real-World Characteristics and Outcomes Among Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) and HER2 Mutations 2024 ·Journal of Thoracic Oncology ·Christina S. Baik, (unknown), Christine M. Lovly, Tejas Patil, Sonia S. Maruti, Stephen A. Stanhope, Stephan Herbertz, Misako Nagasaka	1
5	LBA54 Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2 2024 ·Annals of Oncology ·(unknown), (unknown), Raffaele Califano, SH Lee, (unknown), (unknown), Yuzhuo Wang, (unknown), (unknown), N. Girard, Ryan D. Gentzler, William N. William, (unknown), Misako Nagasaka, (unknown), Shalin Shah, B. Diorio, (unknown), (unknown), Antonio Passaro	6
6	1298P Epidemiological and genomic features of patients (pts) with advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) with HER2/ERBB2 mutations within and outside the tyrosine kinase domain (TKD) 2024 ·Annals of Oncology ·(unknown), (unknown), Misako Nagasaka, Tejas Patil, Sonia S. Maruti, (unknown), (unknown), Stephan Herbertz, Christine M. Lovly	1
7	The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions 2024 ·PubMed ·(unknown), Misako Nagasaka	0
8	Survival and mutational differences based on ESR1 and ESR2 expression in non-small cell lung cancer (NSCLC). 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), Andrew Elliott, Wendy Cozen, Evanthia T. Roussos Torres, Misako Nagasaka, Hirva Mamdani, Gilberto Lopes, Hossein Borghaei, Stephen V. Liu, C. Patrick, Ari M. Vanderwalde, Jorge J. Nieva	1
9	Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC 2024 ·PubMed ·(unknown), Misako Nagasaka	0
10	Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study. 2024 ·Journal of Clinical Oncology ·Sun Min Lim, (unknown), Josiane Mourão Dias, Pei Jye Voon, Soon Hin How, Xiangdong Zhou, (unknown), Bartomeu Massutí, Louise Medley, Misako Nagasaka, David Vicente, Nicolas Girard, Achim Rittmeyer, Dana‐Adriana Botesteanu, Ali Alhadab, Janine Mahoney, Yuehua Zhang, Joshua Bauml, Mahadi Baig, Susan C. Scott	3
11	Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab 2023 ·Allergy Asthma and Clinical Immunology ·Michael A. Lopez, (unknown), Linda Doan, Benjamin J. Lee, (unknown), (unknown), Sai‐Hong Ignatius Ou, Yeşim Yılmaz Demirdağ, Misako Nagasaka	4
12	From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC 2023 ·Critical Reviews in Oncology/Hematology ·Sai‐Hong Ignatius Ou, (unknown), Misako Nagasaka	12
13	PD-23 Comprehensive survey of AACR GENIE cBioPortal database of receptor tyrosine kinase fusion in colorectal carcinoma identified high co-occurring genomic alterations in NTRK1 & RET fusion-positive CRC 2023 ·Annals of Oncology ·Abraham P. Lee, (unknown), (unknown), Misako Nagasaka, Sai‐Hong Ignatius Ou	1
14	Proteolysis targeting chimeras in non-small cell lung cancer 2023 ·Cancer Treatment Reviews ·(unknown), (unknown), Misako Nagasaka	10
15	Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS G12C-Mutant Pancreatic and Lung Cancers 2023 ·Molecular Cancer Therapeutics ·Husain Yar Khan, Misako Nagasaka, Amro Aboukameel, (unknown), Md. Hafiz Uddin, (unknown), (unknown), Ibrahim Azar, Eliza W. Beal, (unknown), Steve Kim, (unknown), Erkan Baloglu, William Senapedis, Bassel F. El‐Rayes, Philip A. Philip, Ramzi M. Mohammad, Anthony F. Shields, Mohammed Najeeb Al Hallak, Asfar S. Azmi	5
16	Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno 2023 ·PubMed ·(unknown), Sai‐Hong Ignatius Ou, Misako Nagasaka	17
17	Neoadjuvant therapy in non-small cell lung cancer 2023 ·Critical Reviews in Oncology/Hematology ·(unknown), (unknown), Misako Nagasaka	17
18	Gastrostomy tube dependence and patient‐reported quality of life outcomes based on type of treatment for human papillomavirus‐associated oropharyngeal cancer: Systematic review and meta‐analysis 2021 ·Head & Neck ·(unknown), Ammar Sukari, Misako Nagasaka, Harold Kim, John D. Cramer	9
19	Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer 2021 ·PubMed ·(unknown), Misako Nagasaka	19
20	COPD and lung cancer incidence in the Women’s Health Initiative Observational Study: A brief report 2020 ·Lung Cancer ·Misako Nagasaka, Amy Lehman, Rowan T. Chlebowski, Brittany Haynes, Gloria Ho, Manali I. Patel, Lori C. Sakoda, Ann G. Schwartz, Michael S. Simon, Michele L. Coté	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact